CSF3 and neutropenia: Although neutropenia rates differ between the phase 3 trials investigating docetaxel in mHSPC patients, the neutropenia rate in the GETUG-15 study was so high that co-treatment with granulocyte colony-stimulating factor had to be initiated [5].